Sarah Stanley normally researches tuberculosis in her lab at UC Berkeley. But when the COVID-19 pandemic shut down all normal research operations on campus, she quickly utilized her own discretionary funds to mobilize her lab and student researchers to study the SARS-CoV-2 live virus.
A partnership with Julia Schaletzky, executive director of Berkeley’s Center for Emerging and Neglected Diseases, has allowed Stanley’s lab to test whether preexisting, FDA-approved drugs would have any effect on killing the virus.
Support work like this by giving to the Vice Chancellor for Research Discretionary Fund.
